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Maria Simonsson1, Andrea Markkula1, Pär-Ola Bendahl1, Carsten Rose2, Christian Ingvar3,4 and Helena Jernström1*Abstract
Purpose: To investigate the association between pre- and postoperative alcohol consumption and risk for early
breast cancer events, since the association between alcohol consumption and prognosis in breast cancer patients
is unclear.
Methods: Alcohol consumption was recorded for 934 primary breast cancer patients who underwent breast cancer
surgery in Lund, Sweden, between 2002 and 2011 and were followed until December 31st 2012. Clinical data were
obtained from medical records and population registries. Pre- and postoperative alcohol consumption was analyzed
in relation to risk for early events.
Results: Median follow-up time was 3.03 years and 100 breast cancer events, 65 distant metastases, and 76 deaths
occurred. Compared to no consumption, any preoperative alcohol consumption was weakly associated with lower
risk for early events, adjusted HR 0.69 (0.45-1.04), distant metastases, 0.60 (0.36-1.00) and death, 0.62 (0.38-1.01). In
the 572 patients without axillary lymph node involvement, any alcohol consumption was not associated with
risk for early events. However, in the 360 patients with axillary lymph node involvement, preoperative alcohol
consumption was associated with lower risk for early events (adjusted HR 0.43 0.24-0.77; Pinteraction = 0.01).
Conclusion: Pre- and postoperative alcohol consumption was weakly associated with lower risk for early breast
cancer events. The data does not support recommending that all breast cancer patients abstain from low to
moderate alcohol consumption.
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The risk for the development of breast cancer in relation
to alcohol consumption has been thoroughly studied.
Alcohol intake, both light and heavy drinking, is now
identified as a risk factor for pre- and postmenopausal
breast cancer (Singletary and Gapstur 2001; Hamajima et al.
2002; Pelucchi et al. 2011; Chen et al. 2011; Seitz et al.
2012). If and how alcohol consumption is associated with
survival and disease recurrence is, however, not yet com-
pletely understood. The results from previous studies are in-
consistent. The majority of studies report no association
between alcohol consumption and overall survival (Holmes
et al. 1999; Dal Maso et al. 2008; Hellmann et al. 2010;
Kwan et al. 2010; Ali et al. 2014) or breast cancer-specific
survival (Dal Maso et al. 2008; Harris et al. 2012;* Correspondence: helena.jernstrom@med.lu.se
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in any medium, provided the original work is pHolm et al. 2013). Some studies report a protective
effect from alcohol consumption on overall survival
(Harris et al. 2012; Reding et al. 2008; Barnett et al.
2008; Flatt et al. 2010) and breast cancer-specific survival
(Ali et al. 2014; Reding et al. 2008; Flatt et al. 2010;
Newcomb et al. 2013), while other studies report higher
breast cancer-specific mortality (Kwan et al. 2010;
Allemani et al. 2011; Vrieling et al. 2012). Five studies have
investigated the association between alcohol consumption
and recurrence of breast cancer (Kwan et al. 2010;
Holm et al. 2013; Flatt et al. 2010; Vrieling et al. 2012;
Kwan et al. 2013), and two of these report an increased
risk of breast cancer recurrence (Kwan et al. 2010;
Holm et al. 2013).
In many populations, alcohol is associated with several
factors that may influence breast cancer mortality. Female
alcohol consumers are more likely to have higher
socioeconomic status (Cederfjäll et al. 2004), lower bodys is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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and higher rates of hormone replacement therapy (HRT)
use (Li et al. 2010), antidepressant use (Graham and
Massak 2007), and complementary alternative medicine
(CAM) use (Hietala et al. 2011). Moreover, increasing
alcohol consumption is associated with smoking
(Hamajima et al. 2002). Several of these factors may
influence hormone levels (Reichman et al. 1993;
Ginsburg 1999; Wayne et al. 2008), which may be
related to breast cancer mortality (MacMahon et al. 1982;
Carmichael 2006; Wurtz et al. 2012). Since lifestyle
factors, such as alcohol consumption, are modifiable,
more personalized recommendations could be given
to the patients based on better knowledge about how
these factors may influence breast cancer mortality
and recurrence.
The aim of the study was to investigate the association
between pre- and postoperative alcohol consumption




This paper is based on data from an on-going population-
based cohort study of women with a first diagnosis of
breast cancer at Skåne University Hospital, Lund, Sweden.
Between October 2002 and December 2011, 1 045 patients
were included in the study at the time of diagnosis, and
were followed until December 31st 2012. The number of
patients included in the analyses in the current study were
934, see Figure 1. Patients diagnosed with another cancer
during the last ten years or with a prior history of breast1045 patients included in the study
934 patients included in the survival analyse
based on preoperative alcohol consumptio
Figure 1 Flowchart illustrating the inclusion and exclusion criteria forcancer were not included. Previous analyses have shown
that patients who were not included were similar to those
patients who were included regarding age at diagnosis and
ER-status (Lundin et al. 2011; Markkula et al. 2012a). Thus,
the patient population is considered to be representative of
breast cancer patients in Sweden. The follow-up rates for
the patients without preoperative treatment included in
the study and who were alive and recurrence-free have
previously been shown to be high (Simonsson et al. 2013).
The following three types of events were considered: 1)
any early breast cancer event including local or regional
recurrence, new breast cancer, or distant metastases; 2)
distant metastases; 3) death. The primary end-point of the
study was any early breast cancer event.
The patients were asked to fill-out questionnaires at a
preoperative clinical visit and again after three to six
months and one, two, three, five, seven, and nine years
postoperatively. Written informed consents were obtained
from all patients, and the study was approved by the
Ethics Committee of Lund University (LU 75-02, LU
37-08, and LU 658-09). At the preoperative visit anthropo-
metric factors were measured by a trained research nurse.
The previously described standardized measurement of
breast volume (Ringberg et al. 2006) was utilized for this
study. The questionnaires included questions about e.g.
reproductive history (Simonsson et al. 2013), use of
exogenous hormones, smoking status (Simonsson et al.
2013), coffee consumption (Simonsson et al. 2013;
Bågeman et al. 2008), and alcohol consumption. Alcohol
consumption was reported in terms of frequency
(never, ≤1 time/month, 2-4 times/month, 2-3 times/week,
4+ times/week) at the preoperative visit, and the numbers 
n
51 patients excluded due to preoperative
treatment
38 patients excluded due to in situ
carcinoma  
8 patients excluded due to metastatic
spread within 3 months after
inclusion
11 patients excluded due to no follow-up
time by December 31, 2012
3  patients excluded due to missing data
on alcohol consumption
Excluded
patients in the different analyses.
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(none, 1-3 drinks, 4-9 drinks, 10-19 drinks, or 20+ drinks)
preoperatively as well as at each follow-up visit. The
questions concerning alcohol consumption were obtained
from the Alcohol Use Disorders Identification Test (AUDIT)
(Saunders et al. 1993).
Information on tumor characteristics (invasive tumor
size, axillary lymph node involvement, histological grade,
and hormone receptor status) was obtained from each
patient’s pathology report. Information on these tumor
characteristics was available for 934 (100%), 932 (99.8%),
933 (99.9%), and 932 (99.8%) patients, respectively. The
tumors were analyzed at the Department of Pathology at
Skåne University Hospital, Lund. ER and PgR status
were determined by immunohistochemistry using the
Dako LSAB kit system (Dako) and the antibodies M7047
(ER) and M3569 (PR; Dako) until December 2009
(Bågeman et al. 2008; Jernström et al. 2009), thereafter
with the antibodies ER (SP1) and PgR (1E2) Ventana
Medical Systems’ (Ventana, AZ, USA) on Ventana
Benchmark Ultra (Ventana Medical Systems). Tumors
with >10% positive nuclear staining were considered
ER + or PgR+. Information concerning any breast cancer
event, i.e., local or regional recurrence, new breast cancer,
and distant metastases, was obtained from patient charts,
pathology reports, and the Regional Tumor Registry.
Deaths and date of death were obtained from the Swedish
Population Registry. Information regarding type of surgery,
sentinel node biopsy, axillary node dissection, and type of
adjuvant treatment was collected from patient charts.
Treatment was administered according to the standard of
care at Skåne University Hospital during the time the
cohort was compiled. Treatment prior to the last follow-up
or prior to any event was recorded.
Data analyses
Statistical analyses were performed using IBM SPSS
statistics 19.0 (Chicago, IL, USA) and Stata (StataCorp.
2013. Stata: Release 12.1. Statistical Software. College
Station, TX: StataCorp LP). For analyses of risk for early
events and distant metastases, patients were followed
from inclusion in the study to the time of the first occur-
rence of the following events: the first subsequent breast
cancer event or distant metastasis, last follow-up, or death
prior to January 1st, 2013. For all-cause mortality, patients
were followed from inclusion to the time of the first
occurrence of the following events: last follow-up or death
from any cause prior to January 1st, 2013.
Alcohol consumption was re-classified into four
groups based on reported weekly alcohol consumption:
no intake (abstainers, 0 drinks/week), low intake (1-3
drinks/week), moderate intake (4-9 drinks/week), and
high intake (10+ drinks/week). Body mass index (BMI)
was calculated as weight, (kg)/height, (m)2.Intra-individualchanges in the amount of alcohol consumption between
visits were analyzed with McNemar-Bowker test. To study
the association between reported alcohol frequency and
intake, a Spearman correlation test was used.
The log-rank test was used to analyze risk for early
events in relation to preoperative alcohol consumption.
Cox regression was used to calculate crude and adjusted
hazard ratios (HR) with 95% confidence intervals (CI)
for early events in relation to alcohol consumption.
Interaction analyses between any preoperative alcohol
consumption and age (50 years or older versus younger),
tumor characteristics and breast cancer treatments were
performed. Treatment after any breast cancer event was
not considered. A series of Cox-regression analyses were
performed to study the relationship between current
alcohol consumption at any visit (any vs null) and risk of
an early breast cancer event. The first analysis examined
the period ranging from the preoperative visit onwards,
whereas the second analysis excluded the period between
the preoperative visit and the first observed postoperative
visit time in the cohort. If the patient, at a follow-up visit,
reported changing her drinking habits since the previous
visit, the dichotomized alcohol consumption variable was
updated and the Cox model refitted. The analysis yields an
updated HR for current alcohol consumption conditional
on being alive and event-free throughout the first time
interval. The third model yields a HR conditional on being
alive and event-free up to the second postoperative
follow-up time in the cohort and so on up to four years of
follow-up. If data on current alcohol consumption at the
time of a postoperative visit was missing, the value from
the previous visit was used in these analyses. The highly
dependent estimated HR:s were plotted against follow-up
time with 95% point-wise confidence bands. A competing
risk analysis was performed using the Stata procedure
stcrreg as described by (Fine and Gray (1999)). The effect
measures in this model are so-called subhazard ratios
(SHR). A P-value <0.05 was considered significant. All
P-values were two-tailed. Nominal P-values are presented
without adjustments for multiple testing.
Results
Patient- and tumor characteristics
Median age at diagnosis was 60.9 years (range 24-99).
As presented in Table 1, increasing preoperative alcohol
consumption was associated with several lifestyle factors.
A shift towards lower alcohol consumption during the
3-6 month visit compared to the preoperative visit was
observed, with 25.2% reporting a decreased consumption,
61.2% a stable consumption and the remaining 13.6% an
increased consumption, p < 0.0001, McNemar-Bowker
test. The tumor characteristics are presented in Table 2.
ER + tumors were more common and hormone receptor
negative tumors less common among patients with a
Table 1 Patient characteristics in a Swedish cohort of 934 patients diagnosed with breast cancer between 2002-2011
Preoperative alcohol consumption during the last week
Non-consumers Moderate High
Patients included in the
survival analyses
Missing 0 drinks/week 1-3 drinks/week 4-9 drinks/week 10+ drinks/week
n = 934 300 (32.1%) 369 (39.5%) 232 (24.8%) 33 (3.5%)
Median Median Median Median Median
(IQR) or % (IQR) or % (IQR) or % (IQR) or % (IQR) or %
Age at diagnosis, yrs 60.6 (52.1-67.6) 0 63.2 (52.8-70.6) 60.9 (52.5-67.7) 59.6 (51.1-65.7) 58.4 (52.9-67.1)
Weight, kgs 69.0 (62.0-78.0) 18 70.0 (60.8-79.1) 68.0 (62.1-78.4) 69.0 (61.0-76.0) 73.0 (60.5-80.0)
Height, m 1.65 (1.62-1.70) 18 1.64 (1.60-1.68) 1.66 (1.62-1.70) 1.67 (1.63-1.70) 1.68 (1.64-1.75)
BMI, kgs/m2 24.9 (22.5-28.2) 20 25.8 (23.0-29.3) 24.9 (22.7-28.4) 24.8 (21.9-27.4) 24.4 (22.0-28.4)
Waist-Hip Ratio 0.85 (0.80-0.90) 28 0.87 (0.81-0.91) 0.85 (0.80-0.89) 0.85 (0.80-0.90) 0.83 (0.79-0.89)
Total breast volume in patients without previous
breast surgery, mL
1000 (650-1550) 138 1000 (700-1580) 1000 (625-1450) 950 (644-1600) 1000 (600-1650)
Age at menarche, yrs 13.0 (12.0-14.0) 4 13.0 (13.5-14.0) 13.0 (12.0-14.0) 13.0 (12.0-14.0) 13.0 (12.3-14.0)
Parous, % 87.6 1 86.3 87.8 90.1 81.8
Age at first full term pregnancy, yrs 25.0 (22.0-28.0) 122 24.0 (20.0-28.0) 25.0 (22.0-28.0) 25.0 (22.5-28.0) 26.0 (23.0-27.0)
Ever use of oral contraceptives, % 71.6 1 63.5 68.8 81.5 84.8
Ever use of HRT, % 44.2 2 37.8 48.1 47.0 42.4
Current smoker prior to surgery, % 20.9 1 17.4 19.8 23.7 33.3
Preoperative daily coffee consumption >2cups/day 81.9 4 77.3 82.2 81.9 93.9
Antidepressants, % 10.6 5 15.0 6.0 11.3 9.1
Preoperative use of Complementary alternative medicine 23.5 9 22.5 19.9 24.5 40.6
Reported frequency of preoperative alcohol consumption 6 rs = 0.70
(P < 0.0001)
Never 95 (10.2) 95 (31.9) 0 (0.0) 0 (0.0) 0 (0.0)
≤ 1 time/month 243 (26.2) 148 (49.7) 76 (20.7) 19 (8.3) 0 (0.0)
2-4 times/month 363 (39.1) 49 (16.4) 224 (61.0) 85 (37.0) 5 (15.2)
2-3 times/week 174 (18.8) 4 (1.3) 66 (18.0) 89 (38.7) 15 (45.5)















Table 2 Tumor characteristics in a Swedish cohort of 934 patients diagnosed with breast cancer between 2002-2011
Preoperative alcohol consumption during the last week
Non-consumers Moderate High
Patients included in the
survival analyses
0 drinks/week 1-3 drinks/week 4-9 drinks/week 10+ drinks/week
n = 934 300 (32.1%) 369 (39.5%) 232 (24.8%) 33 (3.5%)
Neoadjuvant therapy 0 0 0 0 0
Preoperative interstitial laser thermotherapy 0 0 0 0 0
Missing 0 0 0 0 0
No preoperative treatment 934 272 343 217 32
Pathological tumor size
In Situ 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
1 (≤20 mm) 679 (72.47) 215 (71.7%) 271 (73.4%) 169 (72.8%) 24 (72.7%)
2 (21-50 mm) 238 (25.5%) 77 (25.7%) 92 (24.9%) 60 (25.9%) 9 (27.3%)
3 (≥51 mm) 15 (1.6%) 8 (2.7%) 5 (1.4%) 2 (0.9%) 0 (0.0%)
4 (skin or muscular involvement
independent of size)
2 (0.2%) 0 (0.0%) 1 (0.3%) 1 (0.4%) 0 (0.0%)
Invasive tumor size ≥21 mm or
skin or muscular involvement
255 (27.3%) 85 (28.3%) 98 (26.6%) 63 (27.2%) 9 (27.3%)
Missing 0 0 0 0 0
Axillary node involvement
0 572 (61.4%) 188 (63.1%) 227 (61.5%) 134 (57.8%) 23 (69.7%)
1-3 277 (29.5%) 80 (26.8%) 111 30.1%) 78 (33.6%) 8 (24.2%)
4+ 83 (8.9%) 30 (10.1%) 31 (8.4%) 20 (8.6%) 2 (6.1%)
Any axillary lymph node 360 (38.6%) 110 (36.9%) 142 (38.5%) 98 (42.2%) 10 (30.3%)
Missing 2 2 0 0 0
Histological grade
I 229 (24.5%) 64 (21.4%) 103 (27.9%) 54 (23.3%) 8 (24.2%)
II 472 (50.6%) 158 (52.8%) 175 (47.4%) 118 (50.9%) 21 (63.6%)
III 232 (24.9%) 77 (25.8%) 91 (24.7%) 60 (25.9%) 4 (12.1%)
Missing 1 1 0 0 0
Hormone receptor status
ER+ 813 (87.2%) 249 (83.0%) 334 (90.8%) 202 (87.4%) 28 (84.8%)
PgR+ 656 (70.4%) 205 (68.3%) 260 (70.7%) 168 (72.7%) 23 (69.7%)
ER + PgR+ 650 (69.7%) 202 (67.3%) 259 (70.4%) 166 (71.9%) 23 (69.7%)
ER + PgR- 163 (17.5%) 47 (15.7%) 75 (20.4%) 36 (15.6%) 5 (15.2%)
ER-PgR- 113 (12.1%) 48 (16.0%) 33 (9.0%) 27 (11.7%) 5 (15.2%)
ER-PgR+ 6 (0.6%) 3 (1.0%) 1 (0.3%) 2 (0.9%) 0 (0.0%)
Missing 2 0 1 1 0
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with a high intake.
Alcohol consumption in relation to early events, distant
metastases, and all-cause mortality
The median follow-up time until any breast cancer
event, the patient’s completion of the last questionnaire,
or death was 3.0 years (interquartile range 2.0-5.2). For
the total number of events and deaths in each alcoholcategory and for univariable and multivariable models,
see Tables 3. Higher preoperative alcohol consumption
was not associated with lower risk for early breast cancer
events compared to no consumption (Ptrend = 0.53),
Figure 2A and Table 3. Any preoperative alcohol consump-
tion was non-significantly associated with lower risk for
early events compared to no consumption, adjusted HR
0.69 (95% CI 0.45-1.04). The analyses were adjusted for age
at diagnosis, invasive tumor size, axillary lymph node
Table 3 Pre- and postoperative alcohol consumption in relation to risk for early breast cancer events (significant associations are indicated in bold)
Risk for early breast cancer events





Crude HR Adj. HRa No. No. of
events
Crude HR Adj. HRb No. No. of
events
Crude HR Adj. HRb
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Preoperative 934 100 572 49 360 50
None 300 39 Ref. Ref. 188 14 Ref. Ref. 110 24 Ref. Ref.
Any (1+ drinks/week) 634 61 0.66 (0.44-0.99) 0.69 (0.45-1.04) 384 35 1.16 (0.62-2.15) 1.32 (0.69-2.52) 250 26 0.40 (0.23-0.70) 0.42 (0.23-0.75)
0 drinks/week 300 39 Ref. Ref. 188 14 Ref. Ref. 110 24 Ref. Ref.
1-3 drinks/week 369 28 0.51 (0.31-0.83) 0.55 (0.34-0.91) 227 15 0.79 (0.38-1.63) 0.99 (0.47-2.10) 142 13 0.36 (0.18-0.71) 0.37 (0.18-0.74)
4-9 drinks/week 232 30 0.94 (0.58-1.51) 0.90 (0.55-1.48) 134 18 1.93 (0.96-3.90) 1.89 (0.90-3.96) 98 12 0.47 (0.23-0.94) 0.51 (0.25-1.04)
10+ drinks/week 33 3 0.59 (0.18-1.92) 0.70 (0.21-2.32) 23 2 1.13 (0.26-4.98) 1.35 (0.30-6.15) 10 1 0.31 (0.04-2.32) 0.31 (0.04-2.36)
aAdjusted for age at diagnosis (linear), invasive tumor size (<21 mm versus ≥21 mm or skin or muscular involvement independent of size), axillary lymph node involvement (yes/no), tumor grade III (yes/no), ER status
(+/−), BMI (<25.0 kg/m2), preoperative current smoking, and treatment; tamoxifen, aromatase inhibitors, chemotherapy, and radiation therapy (missing data for 26 patients and 0 patients, respectively).
bAdjusted for age at diagnosis, invasive tumor size, tumor grade, ER status, BMI, preoperative current smoking, and treatment; tamoxifen, aromatase inhibitors, chemotherapy, and radiation therapy.

















Figure 2 A-C Preoperative alcohol consumption in relation to
early events, including local or regional recurrence, new breast
cancer, or distant metastases, in: A) All patients – adjusted HR
0.55 (95% CI 0.34-0.91) for 1-3 drinks/week, adjusted HR 0.90 (95% CI
0.55-1.48) for 4-9 drinks/week, and adjusted HR 0.71 (95% CI
0.21-2.32) for 10+ drinks/week. Adjusted HR for any alcohol consumption:
0.69 (95% CI 0.45-1.04). B) Patients with axillary lymph node involvement.
– adjusted HR 0.38 (95% CI 0.19-0.77) for 1-3 drinks/week, adjusted HR
0.52 (95% CI 0.25-1.07) for 4-9 drinks/week, and adjusted HR 0.33 (95% CI
0.04-2.55) for 10+ drinks/week. There were no events in the group
with 10+ drinks/week. Adjusted HR for any alcohol consumption:
0.43 (95% CI 0.24-0.77). C) Patients without axillary lymph node
involvement – adjusted HR 0.93 (95% CI 0.44-1.94) for 1-3 drinks/
week, adjusted HR 1.81 (95% CI 0.87-3.75) for 4-9 drinks/week, and
adjusted HR 1.28 (95% CI 0.28-5.82) for 10+ drinks/week. Adjusted
HR for any alcohol consumption: 1.24 (95% CI 0.66-2.34). Since this
is an on-going cohort, the number of patients decreases as the
follow-up time increases.
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current smoking, and treatments. Any alcohol consump-
tion was also associated with lower risk for early distant
metastases, adjusted HR 0.60 (95% CI 0.36-1.00), and death,
adjusted HR 0.62 (95% CI 0.38-1.01). Of the 76 patients
who died during follow-up, 45 patients had experienced an
event. A competing risk regression analysis using the model
(Fine and Gray (1999)) led to essentially the same results,
adjusted SHR 0.69 (95% CI 0.45-1.05) for 1-9 drinks/week
and adjusted SHR 0.71 (95% CI 0.25-2.05) for 10+ drinks/
week, compared to null consumption.
In order to determine whether the association between
alcohol consumption and risk for early events differed by
age and tumor characteristics, analyses of interaction effects
were performed. There were no significant interactions
between age at diagnosis (50 years or older), ER-positivity,
invasive tumor size (≥21 mm or skin or muscular involve-
ment independent of size), or histological grade III and any
preoperative alcohol consumption (P > 0.1). However, there
was a significant interaction between any alcohol consump-
tion and any axillary lymph node involvement (adjusted HR
2.94 95% CI 1.26-6., adjusted Pinteraction = 0.01). Therefore,
exploratory studies stratified according to axillary lymph
node involvement were performed. Any alcohol consump-
tion was significantly associated with lower risk for early
events among patients with axillary lymph node involve-
ment, Figure 2B, adjusted HR 0.42 (95% CI; 0.23-0.75) but
not in the lymph node negative patients, Figure 2C,
adjusted HR 1.32 (95% CI; 0.69-2.52).
Among the 813 patients with ER + tumors, 480 patients
received tamoxifen and 307 received AI. Out of the 943
patients included in the survival analyses, 238 patients
received chemotherapy and 587 patients received radiation
therapy. Interaction analyses by treatment type and any
preoperative alcohol consumption were performed, but
none were significant (P > 0.05). Further adjustments
for potential confounders (preoperative waist to hip ratio,
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operative coffee consumption, preoperative CAM use,
and preoperative antidepressant use) did not materially
change the results (data not shown).
Current alcohol consumption in relation to early events
The results presented above refer to the association
between preoperative alcohol use, i.e. a characteristic
known at the time of diagnosis, and prognosis. Updated
information on alcohol use at each subsequent visit was
related to prognosis by means of a series of Cox-regression
analyses conditional on event-free survival up to time t,
where t varies from 0 to 4 years of follow-up. The method
is described in more detail in the section Data Analyses.
The results of these analyses are summarized in Figure 3A,
univariable, and Figure 3B, multivariable analyses. Briefly,
the analyses indicate that any alcohol use at the time of
diagnosis was weakly associated with a lower risk of
early breast cancer events (HR < 1.0). For all patients
(left panels), this association leveled off with time and
it was non-significant at the 5% level, but the point
estimate of the HR for any current alcohol consumption
was below 1.0 up to 3 years after diagnosis. The two
panels to the right in the figures show the estimated
conditional HR:s by axillary lymph node status. There was
no association between alcohol consumption at any point
during follow-up in patients with axillary lymph node
negative tumors. However, for patients with axillary lymph
node positive tumors a moderate association was seen
between any alcohol intake and a lower risk for early events.
Discussion
The present study investigated the association between
alcohol consumption and risk for early breast cancer
events in an ongoing cohort of primary breast cancer
patients. The main result was that any preoperative
alcohol consumption was weakly associated with lower
risk for early breast cancer events and early distant
metastases. Using updated information on alcohol use at
each subsequent visit postoperatively by means of a
series of Cox-regression analyses also indicated a weak
association between any alcohol consumption and lower
risk for early events with point estimates of the HR for
any current alcohol consumption below 1.0 up to 3 years
after diagnosis. Secondly, as a result of exploratory
subgroup analyses, any alcohol consumption was associ-
ated with lower risk for early events among patients with
axillary lymph node involvement.
The availability of data on alcohol consumption during
repeated time points during the follow-up period is a
strength of this study. Assessing alcohol consumption
shortly after surgery (which coincides with chemotherapy
or radiation therapy in many patients) may yield too low
estimates of alcohol consumption. Additionally, self-reportedalcohol consumption is often underestimated (Embree and
Whitehead 1993) and may constitute a self-presentational
bias. Consistent with this hypothesis, nearly half of the
patients who claimed to never consume alcohol at the
preoperative visit reported consuming alcohol during at
least one follow-up visit, in the present study. The pre-
operative alcohol consumption in this study is therefore
likely to be underreported. Underreporting would have
biased the results towards the null hypothesis. However,
with updated information of postoperative alcohol
consumption in this study, the results remained.
Several possible mechanisms for the effect of alcohol in
carcinogenesis have been proposed, but the mechanisms
for how alcohol affects the tumor after diagnosis has not
been sufficiently studied. Vorderstrasse et al. reported
in a mouse model study with mammary tumor trans-
plantation, that alcohol consumption, especially in
high but also in moderate doses, protected against
distant metastases compared with water consumption
(Vorderstrasse et al. 2012). One hypothesis might be that
while alcohol consumption confers a higher risk for breast
cancer, it gives rise to tumors with better prognosis, a
phenomenon reported for HRT (Jernström et al. 1999;
Jernström et al. 2003). In the present study, preoperative
moderate alcohol consumption was associated with a lower
frequency of ER–PgR– tumors and a higher frequency of
ER + tumors, but was associated with a better prognosis
irrespective of ER-status. Moreover, an increase in the
plasma ratio of the estrogen metabolites 2OHE to 16αOHE
with increased alcohol consumption has been shown in a
pilot study of the present cohort (Klug et al. 2006). This
may lead to lower stimulation of the ER since 2OHE acts
as weak or anti-estrogen and the 16αOHE1 has been
shown to be procarcinogenic (Schneider et al. 1984).
Additionally, in a subset of the current cohort, seldom
drinkers (<2 times/month) were found to be less adherent
to endocrine therapy (Markkula et al. 2012b), which may
be another explanation for the increased risk for early
events in patients with ER + tumors, but it does not
explain an increased risk in patients with axillary lymph
node involvement. The difference in association between
any alcohol consumption and early events between
patients with and without axillary lymph node involvement
warrants further investigation. The subgroup analysis was
not pre-specified and no adjustments for multiple testing
were performed. One biologically plausible hypothesis
might be that any remaining tumor cells from tumors that
had already metastasized to the axillary lymph nodes at the
time of diagnosis differed with respect to response to
alcohol from those that had metastasized to other sites or
not metastasized at the time of diagnosis. An alternative
hypothesis is that the difference can be attributed to the
higher frequency of early events in patients with axillary
lymph node involvement compared to patients without
AB
Figure 3 A-B Unadjusted and adjusted conditional HR:s for alcohol use. The figures show estimated hazard ratios (HR), with 95% point wise
confidence intervals (CI), for alcohol use (yes vs no) from a series of Cox-regression analyses of time from the preoperative visit to any breast cancer event.
Each dot corresponds to an analysis conditional on event-free survival up to the corresponding observed visit time. Crude (unadjusted) estimates are
shown in Figure 3A and adjusted estimates in Figure 3B. The panels show, from left to right, analyses for all patients, axillary lymph node negative (N0),
and axillary lymph node positive (N+) patients, respectively. The number of patients at risk in each of the two groups at time of diagnosis and four years
post-operatively is shown below each panel, and the corresponding number of events observed is shown between parentheses. The reason why the
counts in N0 and N+ in Figure 3A do not sum to the counts for all patients in the group who report no alcohol use is that the axillary lymph node status
is unknown for two patients.
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therefore be more likely to be detected in this study. Since
this study has a short median follow-up time, the results
warrant confirmation in a study with longer follow-up.
The weak association between any alcohol consumption
and a lower risk for early events found in the present
study is in contrast to the results of five previous studies
(Kwan et al. 2010; Holm et al. 2013; Flatt et al. 2010;
Vrieling et al. 2012; Kwan et al. 2013). Several explanations
could account for the different results from previous
studies, for example the use of different alcohol vari-
ables, such as preoperative alcohol consumption and
consumption during follow-up. Another reason for
inconsistent results from previous studies may be that
different endpoints have been used, such as overall
survival (Holmes et al. 1999; Dal Maso et al. 2008;
Hellmann et al. 2010; Kwan et al. 2010; Harris et al. 2012;
Reding et al. 2008; Barnett et al. 2008; Flatt et al. 2010),
breast cancer specific survival (Dal Maso et al. 2008;
Kwan et al. 2010; Harris et al. 2012; Holm et al. 2013;
Reding et al. 2008; Flatt et al. 2010; Allemani et al. 2011;
Vrieling et al. 2012), and breast cancer recurrence
(Kwan et al. 2010; Holm et al. 2013; Flatt et al. 2010;
Vrieling et al. 2012; Kwan et al. 2013). Furthermore,
no international consensus has been established to
define a standard drink or low-risk alcohol consumption
(Furtwaengler and de Visser 2013). According to the
Swedish recommendations, a standard drink is considered
to consist of 12 grams of ethanol (Furtwaengler and de
Visser 2013), which equals approximately one glass of
wine or 4 cl of 40% liquor. The maximum recommended
alcohol consumption for women in Sweden is 108 g/week,
which equals nine drinks/week (Furtwaengler and de
Visser 2013). This correlates with the classifications made
in this study (10+ drinks/week classified as high intake).
The size of the glasses and the type of beverage were not
specified in the present study. However, a Swedish cohort
of over 10,000 women reported similar median alcohol
intake as the present study (Cederfjäll et al. 2004).
Additionally, the questionnaire did not include questions
about the patients’ consumption in between visits. The
preoperative frequency of alcohol consumption was
therefore also examined in relation to the risk for early
events and distant metastases. The association between
higher frequency of alcohol consumption and both types
of events remained significant among patients with
axillary lymph node involvement (data not shown).
Higher socioeconomic status has been associated with
increased breast cancer-free survival (Halmin et al. 2008),
increased alcohol intake (Cederfjäll et al. 2004), and
decreased levels of smoking (MacMahon et al. 1982).
Conversely, increasing alcohol intake is associated with
smoking (Hamajima et al. 2002). For the present study,
data on socioeconomic status was not available and couldconstitute a potential confounder. Low alcohol consump-
tion, especially in combination with smoking, could thus
be a marker for lower socioeconomic status. However,
according to a recent study, the association between edu-
cational status and breast cancer-free survival might actu-
ally be explained by co-morbidities and lifestyle factors
such as alcohol consumption (Aarts et al. 2012). A weak-
ness of the present study is that the questionnaire did not
include questions concerning history of alcohol consump-
tion or co-morbidities. Some of the non-consumers in the
current cohort may have other co-morbidities that may influ-
ence drinking behaviors, morbidity, and mortality. Moreover,
some of the abstainers in this study could be former alcohol
abusers. Lifelong abstainers and former drinkers have been
reported to have higher morbidity and mortality rates than
light or moderate drinkers (Green and Polen 2001).
Lower reported alcohol consumption was observed
during the 3-6 months visit compared to the pre- or
postoperative consumption. This may be due to nausea
or altered taste in chemotherapy treated patients. The
lower alcohol consumption at the 3-6 months visit
compared to the pre-operative consumption is indirectly
shown graphically in Figures 3A and B as conditional HRs
well below 1.0 pre-operatively approaching the dashed line
HR = 1.0 as the starting time of the analyses increases up
to 1 year. This decreasing effect was mainly driven by
patients switching from the group with best prognosis
(alcohol consumers) to the reference group (non-consumers)
during this time period. The extreme fluctuation of
the estimates around three years post-operatively results
mainly from the fact that the 3-year visit is the last visit
recorded for a large fraction of the patients in the cohort.
Hence, the remaining cohort of patients who contribute
to the estimated effects in the time window from three to
four years is considerably smaller, which is also reflected
in the wider 95% CIs.
This study is based on a prospective cohort of breast
cancer patients, a strength of the study, because retrospect-
ive studies tend to miss patients with early events. Skåne
University Hospital in Lund has a catchment area of nearly
300,000 inhabitants. Since patients with breast cancer
diagnoses are not referred to other hospitals for surgery,
this study population is considered population based.
Conclusions
Alcohol consumption, preoperative as well as postopera-
tive, seems to be weakly associated with fewer early
breast cancer events and fewer distant metastases, but
not with all-cause mortality. Patients have the possibility
of modifying their drinking habits, and the results of this
study do not support recommending all breast cancer
patients to abstain from low to moderate alcohol
consumption. These results warrant confirmation in
studies with longer follow-up.
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